New Publication: HTS Method for Measuring Drug Residence Time
Tuesday, 25 April 2017
View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
- Published in Company, HTS Assays, News
No Comments
Detecting Rho-GEF Activity Using the Transcreener® GDP Assay
Friday, 24 March 2017
Rho GTPases act as molecular switches to regulate the cytoskeletal dynamics underlying cell motility. Rho GEFs (guanine nucleotide exchange factors) positively regulate Rho GTPases by accelerating GDP dissociation and allowing formation of the active GTPase-GTP complex. Active Rho GTPases typically stimulate cell growth and migration, sometimes triggering tumorigenesis or invasion. Selectively disrupting GEF action using
- Published in Company, HTS Assays, Products
What to Look for in an ATPase Assay
Wednesday, 08 March 2017
If your organization utilizes ATPase assays, you must be sure to consider all available options on the market. After all, you must able to have reliable and accurate results, and without the right ATPase assay kit, that’s the best fit for your research this will be difficult. Of course, if you are just now starting
- Published in News
BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services
Wednesday, 22 February 2017
Madison, WI, February 2017 – In response to an increasing demand for characterization and prioritization of compounds downstream of HTS or virtual screening, BellBrook Labs is expanding its Drug Discovery Services to include Lead Discovery in addition to Assay Development. BellBrook will use its proprietary Transcreener® HTS assay platform to accelerate clients’ hit-to-lead and SAR
SLAS Conference 2017 Recap
Tuesday, 14 February 2017
SLAS Conference 2017 Recap Here is what you may have missed… Discussions at the Exhibit Included The expansion of BellBrooks’s Drug Discovery Services What’s new in the field of HTS sssays How Transcreener® Assays are accelerating drug discovery Current challenges to the field of drug discovery and potential solutions moving forward Posters Presented at the Conference
Top Reasons to Choose the Transcreener GTPase Assay
Wednesday, 08 February 2017
While it is true that there may be a number of options available for GTPase assays today, it is important to remember that they are all fundamentally unique. There are some that may be better suited to your needs, while others are going to provide you with better quality and more accurate results. Simple to
- Published in News
What’s New at BellBrook Labs? Find Out at SLAS 2017.
Friday, 20 January 2017
SLAS 2017 Meeting February 4th-8th Walter E. Washington Convention Center Washington, DC Exhibition Visit Booth #245 to: Learn about the expansion of BellBrooks’s Drug Discovery Services Discuss which HTS assays might be a fit for your research Discover how Transcreener® Assays are accelerating drug discovery Poster Presentations A Homogenous, Universal Enzymatic Assay for Histone Methyltransferases Based
Reasons to Use the Transcreener Kinase Assay
Tuesday, 10 January 2017
The Transcreener kinase assays that are available today have a range of benefits, and offer a great solution for many researchers around the world.. These and other Transcreener assays from BellBrook Labs have already been used to great effect by other organizations, and you can receive the same benefits from them. They are a competitive
- Published in News
BellBrook Labs Awarded NIH Funding for Collaboration with University of Utah to Develop Biosensors for Epigenetic Drug Discovery
Monday, 12 December 2016
BellBrook Labs was awarded a Phase I grant of $225,000 to develop biosensors for detection of chromatin modifying enzymes, such as acetyltransferases and methyltransferases, in collaboration with University of Utah chemist Jennifer Heemstra. The collaboration leverages nucleic aptamer technology being developed by Dr. Heemstra to streamline development of assays for epigenetic enzymes being targeted for
- Published in Epigenetics, HTS Assays
Kinase Assays and Applications in Cancer Therapeutic Discovery
Wednesday, 30 November 2016
The ABL1 gene is a special type of gene that encodes a protein tyrosine kinase. It is involved in various cellular processes, including but not limited to cell adhesion, cell division, and cell differentiation. This protein’s activity is adversely regulated by its SH3 domain, which involves the deletion of the region that encodes the domain
- Published in HTS Assays
Recent Posts
-
How Does a Biochemical Kinase Assay Work?
A kinase assay works by simply measuring the ac... -
Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery
Systemic lupus erythematosus (SLE), or l... -
Sensitive Methyltransferase Assay Proves Successful with PRMT4
Histone methyltransferases (HMTs) play a critic... -
Acetyl-CoA Carboxylase Inhibitors: Transcreener ADP Assay Powers Drug Detection Strategy
The impact of Acetyl-CoA carboxylases (ACCs) on... -
Researchers from BellBrook Labs Pen Chapter in Springer’s Rho GTPases: Methods and Protocols
New Protocol from BellBrook Labs: High-Throughp...
